Mark D. Stolper

Mark D. Stolper

DirectoratRadNet· In proxies 2021–2025

Pay in FY2025+50% from the year before · RadNet stock +2.2% the same year

Mark D. Stolper was paid $2.8M in FY2025 (Dec), up 50%. RadNet stock rose 2.2% that year.

Pay$100 in the stock at the end of FY20 → $365
Pay is from the Summary Compensation Table of each RadNet proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Starling OncologyPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. RadNetPublic company · 5 yr
    • Executive Vice President and Chief Financial Officer (principal financial officer)2021 – Present · 5 yrStock in role +292%
  3. Coherus OncologyPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  4. Envision HealthcarePublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  5. Rotech Healthcare Inc.Public company · 10 yr
    • Director2016 – Present · 10 yrNo stock prices for these years
  6. Metropolitan Health Networks, Inc.Public company · 16 yr
    • Director2010 – Present · 16 yrNo stock prices for these years
  7. Coherus BioSciences, Inc.Public company · 4 yr
    • Director2021 – 2025 · 4 yrNo stock prices for these years
  8. Surgalign Holdings, Inc.Public company · 6 yr
    • Director2017 – 2023 · 6 yrNo stock prices for these years
  9. On Track Innovations, Ltd.Public company · 4 yr
    • Director2012 – 2016 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards2

  • Coherus OncologyDirector · 3 yr on the boardIndependentAudit (Chair)—Paid as an executive
  • Starling OncologyDirector · -1 yr on the boardIndependentAudit (Chair)—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?